PepGen (PEPG) News Today → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free PEPG Stock Alerts $13.30 -0.71 (-5.07%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | msn.comHHS panel to vote in Nov. on DMD screening for newbornsMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval ProspectsApril 26, 2024 | markets.businessinsider.comOptimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label ExpansionApril 12, 2024 | insidermonkey.comHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and MoreApril 1, 2024 | marketbeat.comPepGen Inc. (NASDAQ:PEPG) Sees Large Growth in Short InterestPepGen Inc. (NASDAQ:PEPG - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 260,400 shares, an increase of 21.8% from the February 29th total of 213,800 shares. Approximately 1.3% of the company's shares are sold short. Based on an average trading volume of 128,100 shares, the days-to-cover ratio is presently 2.0 days.March 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsMarch 13, 2024 | globenewswire.comPepGen to Participate in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51March 13, 2024 | globenewswire.comPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyMarch 12, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)March 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Increases Position in PepGen Inc. (NASDAQ:PEPG)Adage Capital Partners GP L.L.C. lifted its position in PepGen Inc. (NASDAQ:PEPG - Free Report) by 18.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 680,000 shares of the company'sMarch 9, 2024 | seekingalpha.comPepGen, Inc. (PEPG) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | marketbeat.comWedbush Weighs in on PepGen Inc.'s FY2028 Earnings (NASDAQ:PEPG)PepGen Inc. (NASDAQ:PEPG - Free Report) - Analysts at Wedbush issued their FY2028 earnings estimates for shares of PepGen in a note issued to investors on Wednesday, March 6th. Wedbush analyst L. Chico expects that the company will earn ($0.49) per share for the year. Wedbush has a "Outperform"March 7, 2024 | marketbeat.comPepGen (NASDAQ:PEPG) Price Target Lowered to $20.00 at WedbushWedbush decreased their price target on PepGen from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Thursday.March 7, 2024 | marketbeat.comFmr LLC Lowers Holdings in PepGen Inc. (NASDAQ:PEPG)Fmr LLC decreased its stake in PepGen Inc. (NASDAQ:PEPG - Free Report) by 13.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,365,965 shares of the company's stock after selling 377,985 shares during the quarter. FmMarch 7, 2024 | investorplace.comPEPG Stock Earnings: PepGen Beats EPS for Q4 2023March 6, 2024 | investing.comPepGen's DMD therapy advances to phase 2 trial in the UKMarch 6, 2024 | globenewswire.comPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyFebruary 24, 2024 | marketbeat.comRathbones Group PLC Makes New $315,000 Investment in PepGen Inc. (NASDAQ:PEPG)Rathbones Group PLC purchased a new position in shares of PepGen Inc. (NASDAQ:PEPG - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 62,003 shares of the company's stock, valued at approximately $315,000. RFebruary 21, 2024 | msn.comFDA grants fast track to PepGen’s DM1 treatmentFebruary 20, 2024 | markets.businessinsider.comPepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of DM1February 20, 2024 | finance.yahoo.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 20, 2024 | globenewswire.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 8, 2024 | msn.comPepGen Inc. Secures Funding to Advance Research ProgramsFebruary 8, 2024 | msn.comPepGen Inc. Announces Pricing for Its OfferingFebruary 7, 2024 | tmcnet.comPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockFebruary 7, 2024 | marketwatch.comPepGen Stock Higher After Follow-on OfferingFebruary 6, 2024 | msn.comPepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 dataFebruary 6, 2024 | marketbeat.comPepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 dataPepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapyFebruary 2, 2024 | markets.businessinsider.comTop 4 Health Care Stocks That May Crash This QuarterJanuary 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO PlatformJanuary 30, 2024 | msn.comPepGen stock soars after rival Sarepta reports data for DMD drugJanuary 30, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for PepGen (NASDAQ:PEPG)Wedbush restated an "outperform" rating and issued a $21.00 price objective on shares of PepGen in a research report on Tuesday.January 30, 2024 | marketbeat.comTrading was temporarily halted for "PEPG" at 10:01 AM with a stated reason of "LULD pause."January 20, 2024 | seekingalpha.comPepGen: Long Road AheadJanuary 17, 2024 | finance.yahoo.comDay One Announces Two New Appointments to Board of DirectorsJanuary 17, 2024 | finance.yahoo.comMary Beth DeLena Joins PepGen as General Counsel and SecretaryJanuary 12, 2024 | finance.yahoo.comInstitutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the companyJanuary 8, 2024 | finance.yahoo.comPepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingDecember 18, 2023 | finance.yahoo.comPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)December 2, 2023 | finance.yahoo.comWe Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth CarefullyNovember 15, 2023 | finance.yahoo.comPepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsNovember 11, 2023 | morningstar.comPepGen Inc PEPGNovember 10, 2023 | markets.businessinsider.comFein’s Buy Rating on Biogen: Leqembi’s Potential Growth and Market PenetrationNovember 8, 2023 | msn.comPepGen GAAP EPS of -$0.98November 8, 2023 | benzinga.comPepGen: Q3 Earnings InsightsNovember 8, 2023 | finance.yahoo.comPepGen Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsOctober 17, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Immuneering (IMRX), PepGen Inc. (PEPG) Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade. Register for the imminent briefing here. PEPG Media Mentions By Week PEPG Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PEPG News Sentiment▼0.300.57▲Average Medical News Sentiment PEPG News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PEPG Articles This Week▼31▲PEPG Articles Average Week Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Esperion Therapeutics News Revance Therapeutics News Acelyrin News Theravance Biopharma News Entrada Therapeutics News Neurogene News Lexicon Pharmaceuticals News Fulcrum Therapeutics News Korro Bio News Heron Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PEPG) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
